PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial
Michael J. Koren, Olivier Descamps, Yoshiki Hata, Ellen Margo Hengeveld, G. Kees Hovingh, Ignatios Ikonomidis, Maria D Radu Juul Jensen, Irene H. Langbakke, Fabrice M A C Martens, ANETTE L. SØNDERGAARD, Adam Witkowski, Wolfgang Köenig
Topics & Concepts
MedicinePCSK9PlaceboProprotein convertaseKexinSubtilisinInternal medicineOrally activeAlirocumabPharmacologyCholesterolOral administrationLipoproteinLDL receptorPathologyApolipoprotein A1ChemistryEnzymeAlternative medicineBiochemistryLipoproteins and Cardiovascular HealthCerebrovascular and Carotid Artery DiseasesPeripheral Artery Disease Management